MRI-Guided radiation aims to safely boost liver tumor treatment

NCT ID NCT04020276

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether MRI-guided radiation therapy (SBRT) can be given at higher doses safely to people with cancer that has spread to the liver. Up to 32 participants will receive 5 radiation sessions over 1.5 to 2 weeks. The main goal is to find the highest dose that does not cause serious side effects within the first month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic Body Radiation Therapy (SBRT) with real-time MRI guidance
What this could lead to: If successful, this could establish a safer, more effective radiation dose for treating liver metastases, potentially improving tumor control with fewer side effects.
What could go wrong: This is an early phase I trial with only 32 participants, focused on safety and dosing. It may not lead to better outcomes, and there is a risk of radiation-related toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER METASTASES MRI-GUIDED TREATMENT STEREOTACTIC BODY RADIATION THERAPY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of Wisconsin
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.